Sugi Predict

Sugi Predict / Compounds / SCHEMBL264389

SCHEMBL264389

SCHEMBL264389

CCOC(=O)c1cc(OCCOC)c(OCCOC)cc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ PTGER4 P35408 2/20 0.44
▸ DPP4 P27487 5/20 0.44
▸ GAA P10253 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ TSHR P16473 3/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTR4 Q13639 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ HTR3A P46098 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27984823 0.99 KDM4E (0.46) KDM4EALDH1A1HSD17B10PTGER4DPP4
SCHEMBL17854649 0.96 DPP4 (0.49) KDM4EALDH1A1HSD17B10PTGER4DPP4
SCHEMBL5500188 0.96 KDM4E (0.55) KDM4EALDH1A1HSD17B10PTGER4DPP4
SCHEMBL17836948 0.93 KDM4E (0.42) KDM4EALDH1A1HSD17B10PTGER4DPP4
SCHEMBL641791 0.89 KDM4E (0.39) KDM4EALDH1A1HSD17B10PTGER4DPP4
SCHEMBL4349416 0.89 KDM4E (0.39) KDM4EALDH1A1HSD17B10PTGER4DPP4
SCHEMBL3470108 0.86 KDM4E (0.65) KDM4EALDH1A1HSD17B10GAATSHR
SCHEMBL1013314 0.86 HSD17B10 (0.53) KDM4EALDH1A1HSD17B10DPP4GAA
SCHEMBL299905 0.85 ALDH1A1 (0.46) KDM4EALDH1A1HSD17B10DPP4GAA
SCHEMBL6401543 0.83 KDM4E (0.54) KDM4EALDH1A1HSD17B10DPP4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104193688-A Synthetic method for erlotinib intermediate ESTEVE HUAYI PHARMACEUTICAL CO LTD 2014-12-10 — — CN claimed
WO-2013156835-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF ERLOTINIB HYDROCHLORIDE FORM A LAURUS LABS PRIVATE LIMITED (IN) 2013-10-24 — — WO claimed
US-8133999-B2 Process for preparation of 6, 7-bis(2-methoxyethoxy) quinazolin-4-one UBE INDUSTRIES, LTD. (JP) 2012-03-13 — — US claimed
EP-1650196-B1 PROCESS FOR PRODUCING 6,7-BIS(2-METHOXYETHOXY)-QUINAZOLIN-4-ONE UBE INDUSTRIES (JP) 2011-03-30 — — EP claimed
US-20090253909-A1 PROCESS FOR PREPARATION OF 6, 7-BIS (2-METHOXYETHOXY) QUINAZOLIN-4-ONE UBE INDUSTRIES, LTD. (JP) 2009-10-08 — — US claimed
US-20060276647-A1 Process for producing 6, 7-bis (2-methoxyethoxy)-quinazolin-4-one UBE INDUSTRIES, LTD (JP) 2006-12-07 — — US claimed
EP-1650196-A1 PROCESS FOR PRODUCING 6,7-BIS(2-METHOXYETHOXY)-QUINAZOLIN-4-ONE Ube Industries, Ltd. (JP) 2006-04-26 — — EP claimed
CN-109096208-B Quinazoline derivative and preparation method and application thereof 中国科学院上海有机化学研究所 2021-11-19 — — CN disclosed
US-10053430-B2 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORP. (US) 2018-08-21 — — US disclosed
EP-3103799-B1 QUINAZOLINE DERIVATIVES OSI PHARMACEUTICALS LLC (US) 2018-06-06 — — EP disclosed
EP-2268623-B9 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2018-02-28 — — EP disclosed
US-20170298029-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2017-10-19 — — US disclosed
US-9730937-B2 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2017-08-15 — — US disclosed
US-5821246-A USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER ZENECA LIMITED (GB) 1998-10-13 — — US disclosed
WO-1998043960-A1 SUBSTITUTED 3-CYANO QUINOLINES AMERICAN CYANAMID COMPANY (US) 1998-10-08 — — WO disclosed
US-5747498-A Alkynyl and azido-substituted 4-anilinoquinazolines PFIZER INC. (US) 1998-05-05 — — US disclosed
EP-0817775-A1 QUINAZOLINE DERIVATIVES PFIZER INC. (US) 1998-01-14 — — EP disclosed
EP-0790986-A1 ANILINE DERIVATIVES ZENECA LIMITED (GB) 1997-08-27 — — EP disclosed
WO-1996030347-A1 QUINAZOLINE DERIVATIVES PFIZER INC. (US) 1996-10-03 — — WO disclosed
WO-1996015118-A1 ANILINE DERIVATIVES ZENECA LIMITED (GB) 1996-05-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276647-A1 Process for producing 6, 7-bis (2-methoxyethoxy)-quinazolin-4-one CPS1, CYP3A4, RPS27A KDM4E 287/4885ALDH1A1 1913/4885HSD17B10 1866/4885
US-10053430-B2 RAF kinase modulator compounds and methods of use thereof BRAF, RAF1, ARAF KDM4E 1824/4885ALDH1A1 2803/4885HSD17B10 3559/4885
US-20170298029-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF KDM4E 1824/4885ALDH1A1 2803/4885HSD17B10 3559/4885
US-20090253909-A1 PROCESS FOR PREPARATION OF 6, 7-BIS (2-METHOXYETHOXY) QUINAZOLIN-4-ONE CYP4F11, OGFR, CYP4B1 KDM4E 93/4885ALDH1A1 897/4885HSD17B10 3223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.